文献速递老年慢病共病管理

长期护理机构未感染新冠居民双剂疫苗接种后的抗体与细胞免疫应答

Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study.
PubMed 文献 · Lancet Healthy Longev · 2022-07-04

这项观察性队列研究评估了英国74家长期护理机构员工和居民接种两剂新冠疫苗后的抗体和细胞免疫应答。

要点

  • 既往未感染新冠的长期护理机构老年居民接种两剂疫苗后抗体反应显著低于年轻未感染者及既往感染者。
  • 未感染老年居民的Spike特异性T细胞反应也较年轻未感染者低52%。
  • 研究提示对未感染的长期护理机构居民可能需要加强疫苗接种以优化免疫保护。

核心结论

  • 长期护理机构中既往未感染SARS-CoV-2的老年居民接种两剂新冠疫苗后免疫应答不理想,提示需通过加强针优化免疫保护。

研究设计与样本

  • 观察性队列研究,纳入英国74家长期护理机构的员工和居民,按年龄(<65岁或≥65岁)和感染状态(既往感染或未感染)分层,评估接种两剂疫苗后的抗体和细胞免疫应答。

主要发现

  • 未感染<65岁和≥65岁人群均出现对delta(1.617.2)变异株Spike结合中和作用受损。

临床怎么用

  • 对长期护理机构中既往未感染新冠的老年居民,应考虑接种加强针以提升免疫保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older age and frailty are risk factors for poor clinical outcomes following SARS-CoV-2 infection. As such, COVID-19 vaccination has been prioritised for individuals with these factors, but there is concern that immune responses might be impaired due to age-related immune dysregulation and comorbidity. We aimed to study humoral and cellular responses to COVID-19 vaccines in residents of long-term care facilities (LTCFs). METHODS: In this observational cohort study, we assessed antibody and cellular immune responses following COVID-19 vaccination in members of staff and residents at 74 LTCFs across the UK. Staff and residents were eligible for inclusion if it was possible to link them to a pseudo-identifier in the COVID-19 datastore, if they had received two vaccine doses, and if they had given a blood sample 6 days after vaccination at the earliest. There were no comorbidity exclusion criteria. Participants were stratified by age (<65 years or ≥65 years) and infection status (previous SARS-CoV-2 infection [infection-primed group] or SARS-CoV-2 naive [infection-naive group]). Anticoagulated edetic acid (EDTA) blood samples were assessed and humoral and cellular responses were quantified. FINDINGS: Between Dec 11, 2020, and June 27, 2021, blood samples were taken from 220 people younger than 65 years (median age 51 years [IQR 39-61]; 103 [47%] had previously had a SARS-CoV-2 infection) and 268 people aged 65 years or older of LTCFs (median age 87 years [80-92]; 144 [43%] had a previous SARS-CoV-2 infection). Samples were taken a median of 82 days (IQR 72-100) after the second vaccination. Antibody responses following dual vaccination were strong and equivalent between participants younger then 65 years and those aged 65 years and older in the infection-primed group (median 125 285 Au/mL [1128 BAU/mL] for <65 year olds vs 157 979 Au/mL [1423 BAU/mL] for ≥65 year olds; p=0·47). The antibody response was reduced by 2·4-times (467 BAU/mL; p≤0·0001) in infection-naive people younger than 65 years and 8·1-times (174 BAU/mL; p≤0·0001) in infection-naive residents compared with their infection-primed counterparts. Antibody response was 2·6-times lower in infection-naive residents than in infection-naive people younger than 65 years (p=0·0006). Impaired neutralisation of delta (1.617.2) variant spike binding was also apparent in infection-naive people younger than 65 years and in those aged 65 years and older. Spike-specific T-cell responses were also significantly enhanced in the infection-primed group. Infection-naive people aged 65 years and older (203 SFU per million [IQR 89-374]) had a 52% lower T-cell response compared with infection-naive people younger than 65 years (85 SFU per million [30-206]; p≤0·0001). Post-vaccine spike-specific CD4 T-cell responses displayed single or dual production of IFN-γ and IL-2 were similar across infection status groups, whereas the infection-primed group had an extended functional profile with TNFα and CXCL10 production. INTERPRETATION: These data reveal suboptimal post-vaccine immune responses within infection-naive residents of LTCFs, and they suggest the need for optimisation of immune protection through the use of booster vaccination. FUNDING: UK Government Department of Health and Social Care.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Tut G, Lancaster T, Sylla P, et al. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study. Lancet Healthy Longev. 2022. PMID: 35813280. doi:10.1016/S2666-7568(22)00118-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。